How Analysts Feel About Argenx SE – American Depositary Shares (NASDAQ:ARGX) After Decrease in Sellers?

May 16, 2018 - By Samual Williams

The stock of Argenx SE – American Depositary Shares (NASDAQ:ARGX) registered a decrease of 20.15% in short interest. ARGX’s total short interest was 134,300 shares in May as published by FINRA. Its down 20.15% from 168,200 shares, reported previously. With 117,000 shares average volume, it will take short sellers 1 days to cover their ARGX’s short positions. The short interest to Argenx SE – American Depositary Shares’s float is 0.61%.

The stock decreased 0.85% or $0.79 during the last trading session, reaching $92.64. About 117,691 shares traded. argenx SE (NASDAQ:ARGX) has 0.00% since May 16, 2017 and is . It has underperformed by 11.55% the S&P500.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody therapies for the treatment of autoimmune diseases and cancer. The company has market cap of $2.99 billion. The companyÂ’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It currently has negative earnings. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia.

More important recent argenx SE (NASDAQ:ARGX) news were published by: Globenewswire.com which released: “argenx reports first quarter 2018 financial results and provides business update” on May 09, 2018, also Benzinga.com published article titled: “The Week Ahead In Biotech: PDUFA Dates, IPOs And More”, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” on May 11, 2018. More interesting news about argenx SE (NASDAQ:ARGX) was released by: Globenewswire.com and their article: “argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized …” with publication date: April 24, 2018.

argenx SE (NASDAQ:ARGX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.